MarketScreener Homepage > Equities > Tokyo Stock Exchange > PeptiDream Inc. 4587 JP3836750004

Report

End-of-day quote Tokyo Stock Exchange - 01/25
5910	JPY		+1.37%

01/04

PEPTIDREAM : Partner Kleo Pharmaceuticals to Merge with NYSE-Listed Biohaven Pharmaceuticals

2020

PEPTIDREAM : Licenses Peptide Discovery Platform System to Belgian Pharma Company Janssen

2020

PEPTIDREAM : Takeda Ink Research, License Agreement for Neuromuscular Disease Drug Development

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Tokyo Stock Exchange

01/21/2021	01/22/2021	01/25/2021	01/26/2021	01/27/2021	Date
5920	5830	5910	5760	5860	Last
474200	365600	248600	428900	297900	Volume
-1.17%	-1.52%	+1.37%	-2.54%	+1.74%	Change

Financials

Sales 2020	11 828 M 113 M 113 M
Net income 2020	4 606 M 44,1 M 44,1 M
Net cash position 2020	7 567 M 72,5 M 72,5 M
P/E ratio 2020	160x
Yield 2020	-

Sales 2021	15 336 M 147 M 147 M
Net income 2021	6 832 M 65,5 M 65,5 M
Net cash position 2021	11 615 M 111 M 111 M
P/E ratio 2021	117x
Yield 2021	0,05%

Capitalization	737 B 7 079 M 7 061 M
EV / Sales 2020	61,6x
EV / Sales 2021	47,3x
Nbr of Employees	123
Free-Float	74,2%

More Financials

Company

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and...

Sector

Biotechnology & Medical Research

Calendar

02/10

Earnings Release

More about the company

Notations Surperformance© of PeptiDream Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about PEPTIDREAM INC.

01/04	PEPTIDREAM : Partner Kleo Pharmaceuticals to Merge with NYSE-Listed Biohaven Pha..	MT
2020	PEPTIDREAM : Licenses Peptide Discovery Platform System to Belgian Pharma Compan..	MT
2020	PEPTIDREAM : Takeda Ink Research, License Agreement for Neuromuscular Disease Dr..	MT
2020	Peptidream to Work Together with French Amolyt Pharma on Acromegaly Treatment..	MT
2020	MARKET CHATTER : Peptidream-Janssen Pharmaceuticals Alliance Achieves Developmen..	MT
2020	Peptidream and Four Others Establish Joint Venture to Develop COVID-19 Treati..	MT
2020	Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19..	RE
2020	PEPTIDREAM : Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on ..	AQ
2020	FUJITSU : and PeptiDream Achieve Milestone in Joint Research for Peptide Drug Ca..	AQ
2020	PEPTIDREAM : Our approach to sustainability（esg）	PU
2020	PEPTIDREAM : Corporate Governance Report 07/08/2020	PU
2020	PEPTIDREAM : Non-consolidated Financial Results for the Six Months Ended June 30..	PU
2020	Japan's PeptiDream to work with Merck in developing COVID-19 therapies	RE
2019	Muddy Waters rebukes Japan, French efforts to rein in short sales	RE
2019	Japan pension giant's war on short sellers will have only limited effect - an..	RE

More news

News in other languages on PEPTIDREAM INC.

2019	Muddy Waters éclabousse NMC Health
2015	SANOFI : et PeptiDream s'associent pour développer des peptides thérapeutiques
2013	IPSEN : renforce son partenariat avec PeptiDream dans les maladies endocrinienne..

More news

Provided by Scoopnest.com

Analysis

Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

More Must read

Chart PEPTIDREAM INC.

Duration : Period :

PeptiDream Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends PEPTIDREAM INC.

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Mean consensus	-
Number of Analysts
Average target price
Last Close Price	5 860,00
Spread / Highest target	-
Spread / Average Target	-
Spread / Lowest Target	-

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Patrick Crawford Reid	President & Representative Director
Kiichi Kubota	Chairman
Keiichi Masuya	Director, Manager-Research & Development
Hiroaki Suga	Outside Director
Michio Sasaoka	Independent Outside Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

PEPTIDREAM INC.	12.79%	6 985



GILEAD SCIENCES, INC.	12.39%	83 610
WUXI APPTEC CO., LTD.	36.65%	64 891
VERTEX PHARMACEUTICALS	-4.69%	61 795
REGENERON PHARMACEUTICALS	6.72%	57 427
BEIGENE, LTD.	24.12%	32 675

More Results